These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 1364704)
1. [One year experience of levonorgestrel-releasing intrauterine device]. Lähteenmäki P; Shain RN; Ratsula K; Toivonen J; Holden AE; Rosenthal M; Luukkainen T Duodecim; 1991; 107(1):26-31. PubMed ID: 1364704 [No Abstract] [Full Text] [Related]
2. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Dinger J; Bardenheuer K; Minh TD Contraception; 2011 Mar; 83(3):211-7. PubMed ID: 21310281 [TBL] [Abstract][Full Text] [Related]
3. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)]. Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443 [TBL] [Abstract][Full Text] [Related]
4. Assessment of menstrual blood loss in Belgian users of the frameless copper-releasing IUD with copper surface area of 200 mm2 and users of a copper-levonorgestrel-releasing intrauterine system. Wildemeersch D; Rowe PJ Contraception; 2004 Aug; 70(2):169-72. PubMed ID: 15288224 [TBL] [Abstract][Full Text] [Related]
6. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC). van Vliet HA; Tchaikovski SN; Rosendaal FR; Rosing J; Helmerhorst FM Thromb Haemost; 2009 Apr; 101(4):691-5. PubMed ID: 19350113 [TBL] [Abstract][Full Text] [Related]
7. Assessment of menstrual blood loss in Brazilian users of the frameless copper-releasing IUD with copper surface area of 330 mm2 and the frameless levonorgestrel-releasing intrauterine system. Andrade AT; Souza JP; Andrade GN; Rowe PJ; Wildemeersch D Contraception; 2004 Aug; 70(2):173-7. PubMed ID: 15288225 [TBL] [Abstract][Full Text] [Related]
8. Levonorgestrel-releasing intra-uterine systems (LNG-IUS) and breast cancer. Neven P; Amant F; Poppe W; Van den Broecke R Fertil Steril; 2009 Apr; 91(4):e5; author reply e6. PubMed ID: 19249759 [No Abstract] [Full Text] [Related]
9. [Abdominal migration of a levonorgestrel-releasing intrauterine device. Case report and review of the literature]. Pont M; Lantheaume S J Gynecol Obstet Biol Reprod (Paris); 2009 Apr; 38(2):179-81. PubMed ID: 19303222 [TBL] [Abstract][Full Text] [Related]
10. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Shaamash AH; Sayed GH; Hussien MM; Shaaban MM Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660 [TBL] [Abstract][Full Text] [Related]
11. [Benefits of a levonorgestrel-releasing intrauterine device]. Brun JL; Randriambelomanana J; Quiboeuf E; Dallay D J Gynecol Obstet Biol Reprod (Paris); 2009 May; 38 Spec No 3():F89-92. PubMed ID: 19736664 [No Abstract] [Full Text] [Related]
13. The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. de Sá Rosa e Silva AC; Rosa e Silva JC; Nogueira AA; Petta CA; Abrão MS; Ferriani RA Fertil Steril; 2006 Sep; 86(3):742-4. PubMed ID: 16784745 [TBL] [Abstract][Full Text] [Related]
14. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Jensen JT; Nelson AL; Costales AC Contraception; 2008 Jan; 77(1):22-9. PubMed ID: 18082662 [TBL] [Abstract][Full Text] [Related]
16. [Effects of levonorgestrel-releasing intrauterine system on serum lipids and hepatic function]. He SM Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1321-2, 1324. PubMed ID: 16234121 [TBL] [Abstract][Full Text] [Related]